- Quest Diagnostics Inc (NYSE:DGX) posted a better-than-expected Q1 FY22 adjusted EPS of $3.22, down 14.4% Y/Y, beating the consensus of $2.97.
- Sales came in at $2.61 billion, a decline of 4% Y/Y, slightly lower than the Wall Street estimate of $2.63 billion.
- COVID-19 testing revenues fell 27.6% to $599 million, while Base business revenues improved 6.3% to $2.01 billion.
- Adjusted operating margin compressed to 21.2% from 26% a year ago.
- Outlook: Quest Diagnostics expects FY22 sales of $9.2 billion - $9.5 billion (prior view $9.0 billion - $9.5 billion), compared to the consensus of $9.36 billion.
- Base revenue is expected to increase 4.1% - 6% to $8.35 billion - $8.5 billion (prior view $8.3 billion - $8.5 billion).
- The company anticipates COVID-19 testing revenues to decline (69.3)% - (63.9)% to $0.85 billion - $1.0 billion (prior forecast $0.7 billion - $1.0 billion).
- The company forecasts adjusted EPS of $9.00-$9.50 compared to the prior guidance of $8.65-$9.35, versus the consensus of $9.03.
- Price Action: DGX shares closed 1.89% higher at $138.45 on Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Quest Diagnostics' COVID-19 Testing Sales Decline 28% In Q1; Lifts FY22 EPS Guidance
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks